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Introduction: We investigated the value of lung perfusion imaging
in predicting the risk of developing pulmonary complications after
chemoradiation (CRT) or radiation therapy (RT) for lung cancer.
Methods: Fifty patients who underwent lung perfusion imaging before
RT for lung cancer were included. Planar and single photon emission
computed tomography/computed tomography images of the lungs were
obtained. Lung perfusion score (LPS) was developed to visually grade
localized perfusion defect per lung on a scale of 0 to 4 and perfusion
pattern in the remaining lungs on a scale of 1 to 4. The LPS is the sum
of the score for the localized perfusion defect in each lung plus the score
for the remaining lungs perfusion. LPSs were correlated with pulmo-
nary function tests and the patients were followed for 8 months after
therapy to determine the incidence of grade 2 to 5 symptomatic therapy
related pulmonary complications according to the common terminology
criteria for adverse events (CTCAE 3.0).
Results: Thirty-four patients underwent CRT and 16 underwent RT.
The mean total radiation dose delivered was 56.1  10.4 Gy.
Eighteen patients (36%) suffered from pulmonary complications at
a mean interval of 3.4 months after therapy. Nine patients had grade
2, 7 had grade 3, 1 had grade 4, and 1 had grade 5 pulmonary
complications. The mean LPS was 4.9 in patients who developed
pulmonary complications versus 3.5 in patients who did not (p 
0.01). There were no significant difference between pulmonary
function tests in the patients with pulmonary complications and the
patient without. In addition, there were no significant differences
between the mean lung radiation dose, the volume of lung irradiated
or the percentage of lung receiving greater than 20 Gy between the
two groups.
Conclusions: LPS using lung perfusion imaging is useful for pre-
dicting possible pulmonary complications after CRT or RT in lung
cancer patients.
Key Words: Lung perfusion imaging, SPECT-CT, Lung cancer,
Pulmonary complications.
(J Thorac Oncol. 2008;3: 858–864)
Although the main aim of radiation therapy (RT) is todeliver sufficient radiation to the targeted tumor, the
inclusion of surrounding tissues and organs is unavoidable.
This becomes a challenge when the surrounding tissues or
organs are diseased or compromised by a prior surgical
resection or prior RT. Lung cancer patients, who frequently
suffer from underlying chronic obstructive pulmonary disease
(COPD) or prior resections and/or radiation, present a major
population where RT faces this challenge. RT must be care-
fully and conservatively planned for such patients to mini-
mize comorbidities and complications related to surrounding
lung injury. The reported incidence of radiation pneumonitis
has varied widely in clinical studies ranging from 0 to 54%.1
This wide range is probably the result of differences in the
total radiation doses, number of fractions and fraction dose,
and the differences in associated chemotherapy regimens.
Multiple tests and imaging procedures were proposed
to guide RT planning or to predict the effect of radiation dose
on pulmonary function or degree of tissue damage and
fibrosis in patients with lung cancer.2–6 These procedures
included computed tomography (CT), pulmonary function
tests (PFTs), differential pulmonary function mapping, lung
perfusion and/or ventilation imaging, and oxygen enhanced
magnetic resonance imaging.7,8 Single photon emission com-
puted tomography (SPECT) perfusion and/or ventilation im-
aging of the lungs provides functional information that is not
provided by CT.9 Different areas of the lung may have
different degrees of perfusion and function as demonstrated
using SPECT lung perfusion imaging but appearing of the
same lung density on CT. Also an area of inflammation or
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fibrosis on CT may appear smaller than the actual associated
functional perfusion defect on lung perfusion imaging.10,11
Sparing of the better perfused regions of the lung during RT
planning would be ideal if the tumor size and location allow
modification of RT beams. Lung perfusion SPECT has been
demonstrated to add important functional lung information
for RT planning for different tumors in the chest.12,13 Also,
multiple investigators have also demonstrated a decrease in
pulmonary function after RT using PFTs.14–19 Previous at-
tempts at using lung perfusion scanning to predict post-RT
pulmonary function in comparison with PFTs have been
reported with suboptimal results.20–22 These reports used
planar quantitative lung perfusion images to estimate the resid-
ual post-RT pulmonary function as used for prediction of resid-
ual postoperative pulmonary function after lung resection.
To our knowledge, the ability of lung perfusion imag-
ing to predict clinical patient outcome after chemoradiation
(CRT) or RT alone to the chest has not been investigated. A
method of prospectively identifying patients who cannot
tolerate the changes related to radiation pneumonitis and the
fibrotic permanent late effect of RT is needed. Therefore, in
this study, we investigated the value of lung perfusion
SPECT CT in predicting pulmonary morbidity and compli-
cations after CRT or RT alone in patients with lung cancer.
We developed a lung perfusion score (LPS) that reflects the
degree of loss of perfusion before initiation of RT and
correlated the results with the patients’ clinical outcomes.
MATERIALS AND METHODS
After obtaining approval of the study from The Uni-
versity of Texas M.D. Anderson Cancer Center Institutional
Review Board, 50 consecutive patients with lung cancer who
underwent lung perfusion SPECT CT scanning were obtained
from a prospectively collected data base in the nuclear med-
icine department. The scans were performed within 6 weeks
before the initiation of RT (mean  12 days) except in one
patient it was performed 83 days before RT. The SPECT-CT
scans were considered baseline scans for future repeat scans
to evaluate the extent of lung damage caused by the RT field.
RT planning was performed using simulation CT. Data re-
garding the total RT dose, mean lung dose, total irradiated
lung volume and percentage lung volume receiving greater
than 20 Gy (V20) were collected from the RT plans.
Lung Perfusion SPECT CT
The patients were administered 185 MBq of Tc-99m
Macroaggregated Albumin particles intravenously while ly-
ing in the supine position over a flat-bed imaging table. The
Tc-99m Macroaggregated Albumin dose was thoroughly
shaken immediately before intravenous administration. With
the arms above the head, anterior and posterior static images
were subsequently obtained for 700K counts. This was fol-
lowed by a SPECT CT acquisition using a 6 slice Symbia T6
(Siemens Medical Solutions) equipped with a low-energy
high-resolution collimators. The CT scans were acquired
during shallow breathing using 130 kVp, 90 mAs, 6  2 mm
collimation, and pitch 1.2. The SPECT scans were acquired
using a noncircular orbit and step-and-shoot mode over a 360
degrees arc, in 128 frames, 19 sec/frame at 3-degree angles
into 128  128 matrices. After attenuation and scatter cor-
rection, the SPECT slices were reconstructed using three-
dimensional ordered-subset expectation maximization itera-
tive reconstruction with resolution, scatter and attenuation
correction. Regions of interest were drawn around each lung
on planar views to obtain the geometric means of counts and
split lung perfusion percentage in each lung and in three
zones over each lung (apex, mid, and base).
FIGURE 1. Coronal slices from lung perfusion SPECTs dem-
onstrating A, Localized perfusion defect in the right upper
lung (arrow) equivalent to a score of 1 on the LPS. B, Local-
ized perfusion defect in the left lung equivalent to a score of
2 (short arrow) and in the right lung (long arrow) equivalent
to a score of 3 on the LPS. C, Absent left lung after pneumo-
nectomy equivalent to a score of 4 on the LPS.
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Lung Perfusion Score
The author (IG) developed a LPS that visually grades
the largest localized perfusion defect in either lung as seen on
the SPECT slices on a scale of 0 to 4 and in the remaining
lung fields as seen on the static and SPECT CT images on a
scale of 1 to 4 (Figures 1, 2). The largest localized perfusion
defect score in each lung were added to the remaining lung
perfusion pattern score to provide the total LPS. Thus, the
total LPS ranged from 1 to 12 (Table 1). This developed LPS
provided semiquantitative functional lung results that took
into account both localized perfusion defects and diffuse
underlying parenchymal lung disease. It was developed to
account for balanced diffuse lung disease that is not demon-
strated by the available conventional lung perfusion quanti-
tation software.
Image Interpretation
The reproducibility of the LPS was tested through using
repeat reading of the 50 lung perfusion scans by multiple
readers. Five readers were introduced to the LPS and shown how
to apply it and use it in the image interpretations. The readers
were blinded to the patients’ clinical information except for the
tumor site. The readers mostly used the SPECT images to score
the largest localized perfusion defect in either lung. A combi-
nation of the SPECT CT and the planar images was used to
score the perfusion pattern in the remaining lung fields. The
SPECT/CT images for two patients were not available for
review and only the planar images were used for determining the
LPS.
Clinical Outcomes
The patients’ medical records were reviewed to extract
information about pulmonary complaints or morbidities after
CRT or RT. These included increasing shortness of breath,
symptomatic radiation pneumonitis, increasing oxygen depen-
dence in patients with COPD and respiratory failure. The pa-
tients’ pulmonary complications were categorized as grade 2 to
5 according to the Common Terminology Criteria for Adverse
Events (CTCAE 3.0).23 Patients who had other causes that might
have contributed to their pulmonary complaints including evi-
dence of tumor progression were not considered as CRT or RT
related pulmonary complication. The LPSs for patients with
posttherapy pulmonary complications were compared with
LPSs for patients who did not experience any symptomatic
pulmonary complications or who developed pulmonary compli-
cations related to other etiologies, such as. cardiac etiology. In
addition, LPSs were correlated with PFT results performed at a
median of 13 days of the lung perfusion scan and 23 days of the
start of RT. PFT results were compared in the group of patients
who developed radiation related pulmonary complications ver-
sus the group who did not develop such complications. LPSs
were also specifically correlated with forced vital capacity
(FVC), forced expiratory volume at one second (FEV1), vital
FIGURE 2. Posterior planar images of the chest
demonstrating different patterns of the remain-
ing lung perfusion (A–D) that corresponds to the
different points on the LPS (1–4). A, is homoge-
neous  score of 1, B, is mild heterogeneity 
score of 2, C, is moderate heterogeneity  score
of 3, D, is marked heterogeneity  score of 4.
TABLE 1. Lung Perfusion Score System as a Mean of
Evaluating Lung Function
Largest localized perfusion Defect Score (DS) in each lung as seen on
SPECT
0  No defect
1  Defect 25% of one lung
2  Defect 25–49% of one lung
3  Defect 50–74% of one lung
4  Defect 75–100% of one lung
Remaining Lung Perfusion Score (RLPS) as seen on planar and SPECT
images
1  Homogeneous
2  Mild heterogeneity
3  Moderate heterogeneity
4  Marked heterogeneity
Total Lung Perfusion Score (LPS)  right lung DS  left lung DS  RLPS 
1–12
SPECT, single photon emission computed tomography.
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capacity (VC), and lung diffusion capacity of carbon monoxide
(DLCO) results.
Statistical Analysis
Descriptive statistics for the different components of
the LPSs for the different readers were calculated. Interob-
server agreement was assessed using Shrout and Fleiss’s
intraclass correlation coefficient.24 The correlation coefficient
is defined as the proportion of subject plus reader variance
that is associated with differences among the scores of the
subjects. We used the data from the five readers to calculate
a mean lung score for each patient and then compared the
mean lung score for those with and without complications
using a t test with p values less than 0.05 considered statis-
tically significant. Univariate logistic regression models were
fit to assess the association between complications and co-
variates of interest, including lung score, age, sex, history of
COPD, tumor stage, RT technique, total RT dose, mean lung
dose, and V20. Odds ratios and corresponding 95% confi-
dence intervals were estimated from these models. A multi-
variate analysis was also performed to assess the association
between complications and lung score after taking into ac-
count the other covariates. By using these models we also
constructed receiver operating characteristic (ROC) curves to
assess the ability of the LPS to discriminate between those
with and without complications. Each point on the ROC
curve provides the sensitivity and specificity measures asso-
ciated with a LPS cutpoint in the probability scale. Fisher
exact test was used to test for significant difference in mean
lung volumes included in the RT field in the group of patients
who had radiation related pulmonary complication versus the
group who did not experience such complications. In addition
regression analysis was performed to determine the degree of
correlation between the LPSs and PFT results.
RESULTS
The characteristics of the patients who developed pulmo-
nary complications after RT, the patients who did not experience
such complications and the total study population are summa-
rized in Table 2. Two patients were already oxygen-dependent
from COPD before RT, one had a history of asthma and sleep
apnea and one had a history of idiopathic pulmonary fibrosis.
Thirty-two patients received concurrent CRT, 1 patient received
chemotherapy 2.5 months before RT, another patient received
chemotherapy 4.5 months before RT and 16 patients received RT
alone. Streotactic RT was delivered in four fractions and 2D
conformal and intensity modulated radiation therapy was
delivered in 12 to 35 fractions. The mean lung volume
irradiated in the group of patients who did not experience
pulmonary complications after RT was 1453.5  839.4 cm3
versus in those who developed such complications was
1544.7  822.5 cm3 (p  0.4). The median V20 and median
of mean lung doses were 29.5% and 14.8 Gy in the group of
patients who had pulmonary complications and 29.5% and
18.2 Gy in the group of patients who did not have compli-
cations. In addition, there was no statistically significant
difference in mean lung dose and mean V20 in the two groups
with p  0.70 and 0.76, respectively.
TABLE 2. Characteristics of Patients in the Group Who Developed Radiation Related
Pulmonary Complications vs. the Group of Patients Who Did Not Develop Such
Complications
No RT Pulmonary
Complications (n  32)
RT Pulmonary
Complications (n  18)
Total Study
Population (n  50)
Mean age (yr) 67.2 68.4 67.6
Sex (M:F) 16:16 10:8 26:24
Tumor stage
I 8 (25%) 6 (33.3%) 14
II 1 (3.1%) 0 (0.0%) 1
III 11 (34.4%) 9 (50.0%) 20
IV 5 (15.6%) 0 (0.0%) 5
Recurrence 7 (21.9%) 3 (16.7%) 10
RT technique
Streotactic 11 (34.4%) 6 (33.3%) 17
IMRT 17 (53.1%) 9 (50.0%) 26
3D-conformal 3 (9.4%) 2 (11.1%) 5
Proton therapy 1 (3.1%) 1 (5.6%) 2
Mean total RT dose (Gy) 56.8  9.9 55.1  11.4 56.1  10.4
Mean lung dose (Gy) 15.0  8.1 15.9  7.5 15.5  7.6
Mean V20 (%) 26.5  13.3 27.7  13.5 26.9  13.4
Prior RT 3 (9.4%) 5 (27.8%) 8
Prior surgical resection 3 (9.4%) 2 (11.1%) 5
Prior COPD 9 (28%) 6 (33%) 15
Chemotherapy 25 (78.1%) 9 (50%) 34
IMRT, intensity modulated radiation therapy; V20, percent lung volume irradiated with 20 Gy.
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The mean LPS ranged from 3.5 to 4.7 for the five readers.
One of the readers consistently had the lowest scores whereas
another consistently had the highest scores (Table 3). The
interobserver agreement rate for the LPS was 0.7 for the five
readers. This indicated a good agreement among the readers and
the reproducibility of the LPS by different readers.
Eighteen patients (36%) had developed pulmonary com-
plication at a mean interval of 3.4 months after RT in the
absence of radiologic or clinical evidence of tumor recurrence or
progression. Nine of these patients were grade 2, seven were
grade 3, one was grade 4, and one was grade 5 pulmonary
complication according to the CTCAE 3.0 criteria (Figure 3).
The mean LPS in the patients who developed pulmonary com-
plications was significantly higher than that for the 34 patients
who did not develop pulmonary complications (4.9 versus 3.5,
p 0.01). As the patients’ lung score increased, so did the odds
of the patient having complications (unadjusted OR  1.60,
95% CI: 1.07–2.39). Multivariate analysis; after adjustment for
age, sex, history of COPD, stage of tumor, RT technique, total
RT dose, mean lung dose, and V20; demonstrated significant
association between LPS and radiation related pulmonary com-
plications (OR  3.25, 95% CI: 1.37–7.70). An ROC curve to
assess the ability of the LPS to discriminate between those with
and without pulmonary complications is shown in Figure 4. The
calculated area under the curve is 0.7 which is suggestive of
good predictive value of the LPS in identifying patients who
may have pulmonary complications after CRT or RT. A LPS
cutpoint of more than or equal to 4 provided 78% sensitivity and
59% specificity in identifying patient with potential for devel-
oping pulmonary complications after RT.
Complete PFT results were available for 41 patients
whereas only FEV1 and DLCO results were available for
three additional patients. When PFT results were compared
between the group of patients who developed pulmonary
complication and the group who did not develop pulmonary
complication related to RT, there was no significant differ-
ence in means for FVC, FEV1, VC, DLCO, and TLC. Thus,
PFTs could not identify patients who are at higher risk of
developing pulmonary complications (Table 4). The best
correlation between the LPS and PFTs was obtained with the
FEV1 with r  0.70 followed by the DLCO with r 
0.61. The LPS correlation with VC and FVC were fair at
0.59 and 0.52, respectively.
DISCUSSION
In this study we developed a semiquantitative LPS and
tested its predictive value in risk stratifying patients with lung
cancer who may experience clinically symptomatic pulmo-
nary complications after CRT or RT. A LPS more than 4 is
associated with higher likelihood of developing pulmonary
complications after RT. This should alert a radiation oncol-
ogist to perform a conservative radiation therapy planning to
spare as much functional lung tissue as possible or alterna-
FIGURE 3. Lung perfusion SPECT/CT in a pa-
tient with a small LUL cancer but poor perfu-
sion in the remaining lung who developed re-
spiratory failure after RT.
TABLE 3. Different Readers Scoring of Lung Perfusion Scans According to the LPS Criteria
Reader 1, Mean (SD) Reader 2, Mean (SD) Reader 3, Mean (SD) Reader 4, Mean (SD) Reader 5, Mean (SD)
Total LPS 4.1 (2.0) 4.7 (1.5) 3.5 (1.7) 4.6 (1.8) 4.0 (2.2)
Left lung DS 0.8 (0.9) 0.9 (0.8) 0.5 (0.8) 0.9 (0.8) 0.8 (0.8)
Right lung DS 1.3 (1.1) 1.0 (0.6) 0.9 (0.9) 1.2 (1.0) 1.0 (0.9)
RLPS 2.3 (1.6) 3.2 (1.6) 2.2 (1.3) 2.9 (1.7) 2.6 (1.8)
LPS, Lung Perfusion Score; DS, Defect Score; RLPS, Remaining Lung Perfusion Score.
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tively to use a more targeted RT technique. The group of
patient who developed pulmonary complications after ther-
apy and the group who did not develop such complication
were comparable in their RT metrics (mean lung dose, V20,
irradiated lung volume) because the lung perfusion scan was
obtained only as a baseline study for repeat imaging after RT
to evaluate extent of RT damage. This study population
represented our initial group of patient where lung perfusion
imaging was performed and it did not alter the RT planning
which was performed using the standard simulation CT. Thus
we were able to demonstrate that the degree of decreased
functional lung reserve as reflected in the LPS is an important
predictor of future pulmonary complication after CRT or RT.
LPS was superior to previous attempts at using lung
scintigraphy to predict posttherapy pulmonary function in
patients with lung cancer in that it accounted for both local-
ized perfusion defects and the remaining global lung perfu-
sion. Our study addresses a missing link between the regional
and global lung function after RT that was previously raised
by Fan et al.25 Previous studies focused mostly on visualiza-
tion of localized perfusion defects using lung scintigraphy for
optimization of RT planning.2,9 In addition, most studies
focused on quantification of the localized perfusion defect
size as a percentage of the total lung in conjunction with PFTs
in predicting the pulmonary function.20–22 Both Rubenstein et
al. and Curran et al.21,22 have used a RT planned field
overlapping a planar lung perfusion scan to estimate the
percent lung perfusion defect caused by RT and multiplica-
tions of the remaining percentage of lung perfusion by the
pre-RT FEV1 to predict the expected patient’s FEV1 after
RT. This is similar to the method used for presurgical esti-
mation of residual pulmonary function after lung resection. In
Rubenstein et al. study 20 of 22 patients had measured FEV1s
after RT that were higher than the predicted values using the
planar lung perfusion scan. On the other hand, Curran et al.
demonstrated no change in FEV1 in 53% of their patients
post-RT, an improved FEV1 in 19%, a decline in the FEV1
toward the predicted in 22% and a decline below the pre-
dicted value in 5% at a mean interval of 11 months post-RT.
The suboptimal results with regards to prediction of post-RT
pulmonary function in these 2 studies is probably related to
the use of planar lung images to try to quantify the volumetric
effect of RT on the lung and the use of PFTs to estimate the
status of the remaining lung function. PFTs have their own
limitations to be a useful method of predicting lung function
after CRT. The reproducibility of PFTs is generally consid-
ered to be approximately 5 to 10%26 and it is probably worse
in patients with prior pulmonary compromise. On the other
hand, evaluation of global lung perfusion and function in
such patient population becomes crucial to predict the ability
of the lungs to withstand an additional CRT injury. Thirty-
four percent of our patient population had a history of COPD
or diffuse lung disease and 26% had a history of prior RT or
surgical resection. Our results also demonstrated the inability
of PFT in risk stratify patients for developing RT related
pulmonary complications. There was reasonable correlation
of the LPS with FEV1 but only fair correlation with DLCO,
FVC and VC. Multiple studies have proven PFTs to be a
weak predictor of post-RT pulmonary function and did not
seem to correlate well with patients’ clinical outcome.13,21,27
This is probably because of the complex and changing inter-
active effects of the tumor, RT, chemotherapy, surgical re-
section, and/or underlying lung disease on PFTs performed
for patients with lung cancer.
Our observation is that the size of a localized lung perfu-
sion defect was better visualized and estimated on the SPECT
CT images than on planar images because of the three-dimen-
sional nature of the SPECT display. The CT portion added the
value of attenuation correction of the SPECT slices. CT images
also provided useful adjunctive information to the readers in
scoring the degree of heterogeneity in the remaining lung in the
presence of emphysematous changes on CT. Although not tested
in our study, we anticipate that LPSs obtained from lung perfu-
sion SPECT alone would have similar results in predicting
pulmonary complications post-RT to the chest. A rim of appar-
ent increased tracer concentration at the periphery of the lungs,
particularly at the bases was noted in some cases and was
attributed to attenuation/respiratory motion artifacts. However,
this did not interfere with the LPS and the interpretation of the
images by any of the readers.
We developed the LPS to meet an important clinical need
for an absolute quantitative or semiquantitative measurement
that truly reflects the status of lung perfusion. The present
















FIGURE 4. Receiver operating characteristic (ROC) curves to
assess the ability of the lung perfusion score to discriminate
between patients with and without pulmonary complications.
TABLE 4. Comparison Between PFTs Results in the Patients
Who Developed RT Related Complications vs. the Patients







FVC 85.4 76.8 0.25
FEV1 75.1 61.4 0.08
VC 90.0 76.0 0.08
DLCO 67.2 58.1 0.19
TLC 109.5 113.6 0.48
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perfusion that would mask a diffuse pulmonary lung disease. For
example a patient may have a balanced severe diffuse COPD in
both lungs but still demonstrates equal perfusion percentages in
both lungs whereas the LPS may be high because of the severe
heterogeneity of lung perfusion reflective of the diffuse nature of
the compromised lung perfusion. Thus, the ability to quantify
the degree of heterogeneity in a lung perfusion or ventilation
scan would provide useful information. In addition, because the
lungs are relatively large organ, quantitative software programs
that would provide a more accurate sizing of a localized perfu-
sion defect from the SPECT volume informationwould be superior
to planar images.28 Actually, the readers consistently noted that a
localized perfusion defect is larger in 3D display mode as seen on
SPECT slices than what is perceived on planar images.
One limitation of the LPS was the difference in the
degree of heterogeneity seen on planar versus SPECT images
in the lungs. The readers used a combination of planar images
and SPECT CT to make the best judgment on the score of
heterogeneity of perfusion in the lungs. Despite this limita-
tion, the performance of the LPS in identifying patients
vulnerable for future pulmonary complications was good.
Until more precise quantitative software programs for
quantification and evaluation of lung perfusion and ventilation
are developed, we propose the use of the clinically useful LPS
developed and tested in this study. Our LPS is reflective of the
pulmonary function reserve and can be used for risk stratifica-
tion of patients that are at higher risk of developing pulmonary
complications after CRT or RT to the chest. This may guide
patient management in the use of more conservative RT field or
a more targeted RT technique. It will also alert clinicians toward
closer monitoring of these patients after RT. Future studies to
evaluate the impact of the LPS on changes in RT planning and
consequently on consequent decreases in the incidence of pul-
monary complications are needed.
In conclusion lung perfusion imaging is useful for
predicting possible pulmonary complications after CRT or
RT in lung cancer patients. Patients with pretherapy LPS of
more than 4 are more likely to develop pulmonary compli-
cations after RT or CRT.
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